Amgen Inc.

Jason C Long

Leslie Phillip Miranda

Christopher Michael Tegley

Bin Wu

Elizabeth M Doherty

James Richard Falsey

Kaustav Biswas

Kelvin C Sham

Fang-Tsao Hong

Jerry Ryan Holder

Essa Hu Harrington

Justin K Murray

Irwin Chen

Malgorzata Wanska

Su Chong

Kelvin Sham

Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.

Peptide PAC1 antagonists

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Potent and selective inhibitors of Nav1.7

Growing community of inventors

Newbury Park, CA, United States of America

Jason C Long